Nuvectis Pharma Inc
NVCT
Company Profile
Business description
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Contact
1 Bridge Plaza
2nd Floor, Suite 275
Fort LeeNJ07024
USAT: +1 201 614-3150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks
Downgrade for ASX listed fund manager as redemptions pile on
Persistent outflows erode earnings outlook.
stocks
Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?
Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,940.40 | 100.00 | 1.13% |
| CAC 40 | 7,956.70 | 22.00 | 0.28% |
| DAX 40 | 25,622.61 | 239.99 | 0.95% |
| Dow JONES (US) | 52,002.41 | 175.28 | -0.34% |
| FTSE 100 | 10,881.90 | 41.55 | 0.38% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,140.03 | 572.99 | -2.14% |
| Nikkei 225 | 65,324.29 | 898.34 | 1.39% |
| NZX 50 Index | 13,753.73 | 79.07 | -0.57% |
| S&P 500 | 7,659.44 | 84.62 | -1.09% |
| S&P/ASX 200 | 8,806.70 | 87.00 | 1.00% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |